| Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions (NCT05361694) | University of Miami | 2022-04-12 |
| A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH (NCT05283993) | Peking University First Hospital | 2021-07-01 |
| A Study of a Plant-Based Diet in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM) (NCT04920084) | Memorial Sloan Kettering Cancer Center | 2021-06-03 |
| Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma (NCT04850846) | Dana-Farber Cancer Institute | 2021-04-27 |
| MGUS, SMM, and MM Patient Experience With Coronavirus 19 (COVID-19) Survey (NCT04727294) | HealthTree Foundation | 2021-01-22 |
| Screening to Improve Survival in AL Amyloidosis (NCT04615572) | Tufts Medical Center | 2020-08-28 |
| Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to Establish New Recommendations. (NCT04144387) | Intergroupe Francophone du Myelome | 2020-02-11 |
| A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM) (NCT03815279) | Landspitali University Hospital | 2019-06-24 |
| Denosumab for Smoldering Multiple Myeloma (NCT03839459) | University of Rochester | 2019-04-19 |
| PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma (NCT03850522) | Lene Meldgaard Knudsen | 2019-02-18 |
| Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant (NCT03289299) | International Myeloma Foundation | 2018-05-25 |
| Registry for Adults With Plasma Cell Disorders (PCD's) (NCT03717844) | UNC Lineberger Comprehensive Cancer Center | 2018-02-09 |
| Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma (NCT03236428) | Dana-Farber Cancer Institute | 2017-11-24 |
| A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM (NCT02886065) | Massachusetts General Hospital | 2017-03-07 |
| A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma (NCT02903381) | Dana-Farber Cancer Institute | 2016-10-20 |
| Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma (NCT02916771) | Dana-Farber Cancer Institute | 2016-10-01 |
| Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma (NCT02415413) | PETHEMA Foundation | 2015-05-01 |
| E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma (NCT02279394) | Dana-Farber Cancer Institute | 2014-12-11 |
| Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome (NCT02269592) | Dana-Farber Cancer Institute | 2014-08-01 |
| Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma (NCT01955395) | Dana-Farber Cancer Institute | 2013-10-01 |
| A Phase II Study of BI-505 in Smoldering Multiple Myeloma (NCT01838369) | BioInvent International AB | 2013-03-01 |
| Imaging Studies and the Development of Multiple Myeloma (NCT01571726) | National Cancer Institute (NCI) | 2012-03-27 |
| Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma (NCT01441973) | Bristol-Myers Squibb | 2011-12-28 |
| Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma (NCT01302886) | Novartis Pharmaceuticals | 2011-05-01 |
| Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma (NCT01169337) | National Cancer Institute (NCI) | 2011-01-24 |
| A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma (NCT01248455) | National Cancer Institute (NCI) | 2010-11-01 |
| Imaging in MGUS, SMM and MM (NCT01237054) | National Cancer Institute (NCI) | 2010-10-17 |
| Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders (NCT01177527) | Dana-Farber Cancer Institute | 2009-12-30 |
| Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM) (NCT00899353) | Marshall University | 2008-08-01 |
| Efficacy and Safety of Statin on the Course of Progressive Smoldering Multiple Myeloma (NCT00503763) | Meir Medical Center | 2007-09-01 |
| Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant (NCT00114101) | National Cancer Institute (NCI) | 2004-12-15 |
| Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma (NCT00099047) | National Cancer Institute (NCI) | 2004-11-01 |
| Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma (NCT00112827) | City of Hope Medical Center | 2004-11-01 |